Zhengye Biotechnology Holdings/$ZYBT

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Zhengye Biotechnology Holdings

Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry, and other vaccines.

Ticker

$ZYBT
Sector
Health
Primary listing
NASDAQ

Employees

277
Headquarters
Jilin, China
Website
www.jlzybio.com

ZYBT Metrics

BasicAdvanced
$318M
194.24
$0.03
-
-

Bulls say / Bears say

On February 25 and March 21, 2025, Zhengye secured two Category I New Veterinary Drug approvals—a live Mycoplasma bovis vaccine and a pentavalent poultry vaccine—granting up to five years of market exclusivity and validating its R&D leadership (PRNewswire).
The IPO raised $6 million on January 8, 2025, and the underwriter fully exercised the 225,000-share over-allotment option on January 14, 2025, bringing total gross proceeds to $6.9 million, strengthening the balance sheet for growth initiatives (Nasdaq).
Proceeds from the offering will be used for acquiring vaccine production companies and funding R&D projects, positioning Zhengye to expand its manufacturing footprint and accelerate pipeline development (Nasdaq).
Fiscal year 2024 net revenues fell 12% to RMB186.4 million and net income plunged 64% to RMB13.5 million, reflecting reduced profitability amid market headwinds (PRNewswire).
On May 20, 2025, Zhengye received a Nasdaq Delinquency Letter for late filing its 2024 Form 20-F, risking potential delisting if compliance is not restored by the deadline (Nasdaq).
The company’s decision to curtail swine vaccine sales to its largest customer to mitigate concentration risk led directly to the 12% revenue drop, underscoring vulnerability from customer concentration (PRNewswire).
Data summarised monthly by Lightyear AI. Last updated on 25 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ZYBT

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs